|Last Price$56.26||Day Change (%)0.37%|
|Open Price$56.45||Day Change ($)0.21|
|Day Range55.93–56.95||52-Week Range44.60–58.14|
As of Wed 04/16/2014 03:44 PM EST | USD
Merck ’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection
Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck ’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014
Merck CEO Frazier: Consumer Unit Draws 'Substantial' Interest -Fox News
Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
These managers have planned for the future—and protected strong records—by placing an emphasis on succession planning.
Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...
Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29
Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.